PACB
Pacific Biosciences of California Inc
$
1.130
- Overview
- Forecast
- Valuation
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.130
Open
1.120
VWAP
1.10
Vol
6.21M
Mkt Cap
339.05M
Low
1.080
Amount
6.86M
EV/EBITDA(TTM)
--
Total Shares
272.36M
EV
596.61M
EV/OCF(TTM)
--
P/S(TTM)
2.01
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q2
FY2025Q1
41.38M
+3.54%
--
--
37.67M
+4.61%
--
--
36.90M
-4.92%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Pacific Biosciences of California, Inc. (PACB) for FY2025, with the revenue forecasts being adjusted by -14.4% over the past three months. During the same period, the stock price has changed by -27.56%.
Revenue Estimates for FY2025
Revise Downward
-14.4%
In Past 3 Month
Stock Price
Go Down
-27.56%
In Past 3 Month
10 Analyst Rating
85.84% Upside
Wall Street analysts forecast PACB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACB is 2.10 USD with a low forecast of 1.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
5 Hold
0 Sell
Moderate Buy
85.84% Upside
Current: 1.130
Low
1.50
Averages
2.10
High
3.00
85.84% Upside
Current: 1.130
Low
1.50
Averages
2.10
High
3.00
Canaccord Genuity
Kyle Mikson
Strong Buy
Maintains
$3
2025-04-10
Reason
Canaccord Genuity
Kyle Mikson
Price Target
$3
2025-04-10
Maintains
Strong Buy
Reason
Scotiabank
Sung Ji Nam
Buy
Maintains
$6 → $2
2025-03-25
Reason
Scotiabank
Sung Ji Nam
Price Target
$6 → $2
2025-03-25
Maintains
Buy
Reason
Scotiabank analyst Sung Ji Nam lowered the firm's price target on PacBio to $2 from $6 and keeps an Outperform rating on the shares. The company's FY24 was disappointing, and this year could have driven significant revenue reacceleration had it not been for near-term U.S. academic funding uncertainty dampening growth, the analyst tells investors. The firm continues to believe the company is well positioned to innovate faster, cheaper, easier, and more insightful NGS capabilities.
Piper Sandler
David Westenberg
Hold
Reiterates
$2.5 → $2
2025-02-20
Reason
Piper Sandler
David Westenberg
Price Target
$2.5 → $2
2025-02-20
Reiterates
Hold
Reason
Piper Sandler lowered the firm's price target on PacBio to $2 from $2.50 following quarterly results. The firm keeps a Neutral rating on the shares.
Goldman Sachs
Matthew Sykes
Hold
Maintains
$1.75 → $1.5
2025-02-18
Reason
Goldman Sachs
Matthew Sykes
Price Target
$1.75 → $1.5
2025-02-18
Maintains
Hold
Reason
Stephens & Co.
Mason Carrico
Buy
Reiterates
$2.5
2025-02-18
Reason
Stephens & Co.
Mason Carrico
Price Target
$2.5
2025-02-18
Reiterates
Buy
Reason
Stephens & Co.
Mason Carrico
Buy
Reiterates
$2.5
2025-02-14
Reason
Stephens & Co.
Mason Carrico
Price Target
$2.5
2025-02-14
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Pacific Biosciences of California Inc (PACB.O) is -1.53, compared to its 5-year average forward P/E of 2.82. For a more detailed relative valuation and DCF analysis to assess Pacific Biosciences of California Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
2.82
Current PE
-1.53
Overvalued PE
60.43
Undervalued PE
-54.79
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-13.60
Current EV/EBITDA
-3.22
Overvalued EV/EBITDA
-1.11
Undervalued EV/EBITDA
-26.10
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
16.15
Current PS
2.12
Overvalued PS
30.39
Undervalued PS
1.91
Financials
Annual
Quarterly
FY2024Q4
YoY :
-32.79%
39.22M
Total Revenue
FY2024Q4
YoY :
-23.84%
-63.18M
Operating Profit
FY2024Q4
YoY :
-102.89%
2.37M
Net Income after Tax
FY2024Q4
YoY :
-103.23%
0.01
EPS - Diluted
FY2024Q4
YoY :
-45.85%
-32.27M
Free Cash Flow
FY2024Q4
YoY :
+6.38%
13.84
Gross Profit Margin - %
FY2024Q4
YoY :
+3.10%
-137.81
FCF Margin - %
FY2024Q4
YoY :
-104.30%
6.04
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
30.9K
USD
3
3-6
Months
793.1K
USD
4
6-9
Months
34.1K
USD
1
0-12
Months
105.8K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 465.1% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
2.4M
Volume
2
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
20.4M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
4
3.6M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
30.9K
USD
3
3-6
Months
793.1K
USD
4
6-9
Months
34.1K
USD
1
0-12
Months
105.8K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PACB News & Events
Events Timeline
2025-05-05 (ET)
2025-05-05
09:07:47
PacBio announces collaboration to implement PacBio HiFi WGS
2025-04-28 (ET)
2025-04-28
09:09:52
PacBio announces plans to improve methylation detection in HiFi Chemistry
2025-04-22 (ET)
2025-04-22
09:06:54
PacBio to be technology partner to DAC's NADR project
Sign Up For More Events
Sign Up For More Events
News
3.0
12:38 PMSeekingAlphaPacific Biosciences of California Q1 2025 Earnings Preview
7.5
05-05NewsfilterFirst Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand
5.0
05-01BenzingaCathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant
Sign Up For More News
People Also Watch
ABSI
Absci Corp
2.660
USD
+0.38%
HCAT
Health Catalyst Inc
3.970
USD
-2.46%
IHRT
iHeartMedia Inc
1.100
USD
+0.92%
NEWT
NewtekOne Inc
9.910
USD
+3.88%
LOCO
El Pollo Loco Holdings Inc
8.880
USD
-1.00%
HVT
Haverty Furniture Companies Inc
18.810
USD
-0.21%
EB
Eventbrite Inc
2.180
USD
+3.32%
SSBK
Southern States Bancshares Inc
34.500
USD
-0.61%
KLTR
Kaltura Inc
2.200
USD
-0.45%
ARQQ
Arqit Quantum Inc
16.000
USD
+4.58%
FAQ
What is Pacific Biosciences of California Inc (PACB) stock price today?
The current price of PACB is 1.13 USD — it has increased 2.73 % in the last trading day.
What is Pacific Biosciences of California Inc (PACB)'s business?
What is the price predicton of PACB Stock?
What is Pacific Biosciences of California Inc (PACB)'s revenue for the last quarter?
What is Pacific Biosciences of California Inc (PACB)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Pacific Biosciences of California Inc (PACB)'s fundamentals?
How many employees does Pacific Biosciences of California Inc (PACB). have?